1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Medicamen Biotech Limited

Medicamen Biotech Limited

MEDICAMEQ.NS
Medicamen Biotech LimitedIN flagNational Stock Exchange of India
265.70
INR
-7.00
- -
3.60BMarket Cap

Total Valuation

Medicamen Biotech Limited carries a market capitalization of 3.60B, placing it among publicly traded companies globally. Its enterprise value stands at 3.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.60B
Enterprise Value3.29B

Share Statistics

Medicamen Biotech Limited currently has 13.56M shares outstanding.

Shares Outstanding13.56M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Medicamen Biotech Limited trades at a trailing price-to-earnings ratio of 30.28. The price-to-sales ratio is 1.58, and the price-to-book ratio stands at 23.02.

PE Ratio30.28
PS Ratio1.58
PB Ratio23.02
P/TBV Ratio1.14
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Medicamen Biotech Limited trades at an EV/EBITDA multiple of 26.58 and an EV/FCF ratio of 114.99. The EV/Sales ratio of 1.66 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 26.58 provides insight into valuation relative to core operating earnings.

EV / Sales1.66
EV / EBITDA26.58
EV / EBIT26.58
EV / FCF114.99

Financial Position

Medicamen Biotech Limited maintains a current ratio of 2.54, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.34, indicating elevated leverage, while an interest coverage ratio of 3.54 demonstrates adequate ability to service its debt obligations.

Current Ratio2.54
Quick Ratio0.36
Debt / Equity17.34
Debt / EBITDA3.86
Interest Coverage3.54

Financial Efficiency

Medicamen Biotech Limited posts a return on equity of 16.82 and a return on invested capital of 3.51.

Return on Equity (ROE)16.82
Return on Assets (ROA)3.08
Return on Invested Capital (ROIC)3.51
Return on Capital Employed (ROCE)13.33
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.54

Taxes

Over the trailing twelve months, Medicamen Biotech Limited has paid 21.88M in income taxes, reflecting an effective tax rate of 18.26.

Income Tax21.88M
Effective Tax Rate18.26

Stock Price Statistics

Medicamen Biotech Limited's stock has declined approximately -39.12247% over the past 52 weeks. The 50-day moving average sits at 259.22, while the 200-day moving average is 327.87.

Beta (5Y)N/A
52-Week Price Change-39.12247%
50-Day Moving Average259.22
200-Day Moving Average327.87
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Medicamen Biotech Limited generated 1.98B in revenue and converted that into 103.12M in net income, yielding earnings per share of 7.01. EBITDA reached 123.69M, while operating income came in at 123.69M.

Revenue1.98B
Gross Profit959.98M
Operating Income123.69M
Pretax Income119.84M
Net Income103.12M
EBITDA123.69M
EBIT123.69M
Earnings Per Share (EPS)7.01

Balance Sheet

Medicamen Biotech Limited holds 312.64M in cash and equivalents against 477.84M in total debt, resulting in a net debt position of 165.19M. Total book value stands at 135.63M, with working capital of 1.36B providing operational flexibility.

Cash & Cash Equivalents312.64M
Total Debt477.84M
Net Debt165.19M
Equity (Book Value)135.63M
Book Value Per Share9.70
Working Capital1.36B

Margins

Medicamen Biotech Limited operates with a gross margin of 48.54, reflecting its pricing power and cost economics. The operating margin of 6.25 and net profit margin of 5.21 provide insight into operational efficiency.

Gross Margin48.54
Operating Margin6.25
Pretax Margin6.06
Profit Margin5.21
EBITDA Margin6.25

Scores

Medicamen Biotech Limited posts an Altman Z-Score of 3.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.02